AC Immune SA
ACIUNasdaq
$2.20
↑ +0.9%Jul 17 close · end-of-day
Price
1Y↑ +6.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
AC Immune SA discovers, designs, and develops medicines and diagnostic products. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease. It is also developing ACI-24, an anti-Abeta vaccine candidate, as well as completed Phase Ib clinical study for Down syndrome. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases.
- CEO
- Andrea Pfeifer
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 140
- Website
- acimmune.com
Management & directors
- Zuegel MartinInterim CEO
- Pfeifer AndreaChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | Twyman Roy Ervin | Award | 16,568 | $0.00 | $0.00 | filing |
| 2026-06-11 | AGUIAR-LUCANDER RENEE | Award | 16,568 | $0.00 | $0.00 | filing |
| 2026-06-11 | Zuegel Martin· Interim CEO | Award | 33,136 | $0.00 | $0.00 | filing |
| 2026-06-11 | Buetler Monika | Award | 17,751 | $0.00 | $0.00 | filing |
| 2026-06-11 | June Carl Howard | Award | 16,568 | $0.00 | $0.00 | filing |
| 2026-05-15 | Pfeifer Andrea· Chief Executive Officer | Sale | 10,000 | $2.79 | $27,935.00 | filing |
| 2026-04-15 | Pfeifer Andrea· Chief Executive Officer | Sale | 10,000 | $3.14 | $31,425.00 | filing |
| 2026-04-15 | Pfeifer Andrea· Chief Executive Officer | Buy | 10,000 | $3.14 | $31,425.00 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.